| symbol |
GNMx |
|---|
| 会社名 | Aevi Genomic Medicine Inc （アエヴィ・ジェノミック・メディシン） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Biotechnology: Biological Products (No Diagnostic Substances)
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Aevi Genomic Medicine Inc. formerly Medgenics Inc. is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). . アエヴィ・ジェノミック・メディシンは米国のバイオ医薬品企業。臨床段階で、遺伝子医療に従事する。同社は「注意欠陥・多動性障害(ADHD)」を治療する「NFC-1」を開発し、遺伝子異常に起因する「22q11.2欠失症候群」の治療にも取り組む。また、タンパク質の生産と配送を繰り返すために患者自身の皮膚を使う治療も開発する。本社はペンシルベニア州ウェイン。 Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.
|
|---|
| 本社所在地 | 435 Devon Park Drive Suite 715 Wayne PA 19087 USA |
|---|
| 代表者氏名 | Michael F. Cola マイケル・F・コーラ |
|---|
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
|---|
| 電話番号 | +1 610-254-4201 |
|---|
| 設立年月日 | 36526 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 17人 |
|---|
| url | www.aevigenomics.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/gnmx |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -32.65200 |
|---|
| 終値（lastsale） | 1.245 |
|---|
| 時価総額（marketcap） | 73879210.095 |
|---|
| 時価総額 | 時価総額（百万ドル） 71.20888 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 52.05788 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -32.66400 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aevi Genomic Medicine Inc revenues was not reported. Net loss decreased 11% to $16.9M. Lower net loss reflects Other General_Administration expense decrease of 13% to $3.8M (expense) Stock-based Compensation in SGA decrease of 12% to $889K (expense) Stock-based Compensation in R&D decrease of 16% to $646K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.51 to -$0.28. |
|---|